AbbVie Seeks FDA Approval for Tavapadon in Parkinson’s Treatment

AbbVie asked the United States Food and Drug Administration to approve a new medication for Parkinson’s called tavapadon. This is a once daily oral treatment. The company believes tavapadon could help people across different stages of Parkinson’s, including those early after diagnosis and those later on who already take levodopa. Tavapadon targets dopamine D1 and D5 receptors. In simple terms, it lightly switches on parts of the brain’s dopamine system that are affected in Parkinson’s. It is not the same as levodopa. It works in a different way by directly stimulating these receptors rather than topping up dopamine levels. The idea is to improve movement control while keeping side effects manageable. AbbVie based its filing on a group of Phase 3 trials called TEMPO. Two trials, TEMPO 1 and TEMPO 2, tested tavapadon in people with early Parkinson’s either on its own or alongside a common add on called an MAO B inhibitor. In both trials, people taking tavapadon improved more than those on placebo on a standard score that combines daily function and movement performance after 26 weeks. This measure is known as MDS UPDRS Parts II and III combined. A third trial, TEMPO 3, looked at tavapadon added to stable levodopa in people with motor fluctuations. These are the ups and downs when symptoms return between doses. In this study, tavapadon increased good on time without troublesome involuntary movements compared with placebo. On time refers to periods when symptoms are well controlled. The company also included interim information from an open label extension, TEMPO 4, which is following people on tavapadon for longer to understand ongoing safety and benefit. Across the Phase 3 programme most side effects were reported as mild or moderate. Serious side effects and deaths were uncommon and similar between tavapadon and placebo in these trials. The most common issues were nausea, headache and dizziness when tavapadon was used without levodopa, and nausea and dyskinesia when it was used together with levodopa. As with any press release summary, the exact numbers and event rates will matter, and regulators will examine those details in full. If the FDA agrees that the benefits outweigh the risks, tavapadon would give doctors another oral option. For people early after diagnosis, it could be used on its own or with other medications. For people further along who rely on levodopa but still have wearing off, it could be used as an add on to smooth control. None of this is a guarantee of approval, and the agency will assess the quality and consistency of the TEMPO data and the longer term safety follow up. For context, Parkinson’s affects more than eleven million people worldwide and leads to tremor, stiffness, slowness and balance problems. As the condition advances, many people face time each day when medicines no longer control symptoms well, and some develop involuntary movements. An effective once daily medication that meaningfully improves function or extends good on time without adding heavy side effects would be a welcome addition to the toolkit. In short, AbbVie has asked for approval of tavapadon on the back of three positive late stage trials. The studies point to improved function in early Parkinson’s and longer good control time when added to levodopa in later Parkinson’s. Safety looks manageable in the company summary, although the details and longer follow up are important. The next step is the FDA review, which will decide whether this medicine can be offered in routine care in the United States.